Position in SPRY
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,093,967
-$1,837,091 QoQ
Shares Held
136,235
-45.9% QoQ
Ownership
0.137%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SPRY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Eversept Partners, LP holds $674,697,695 across 57 Biotechnology names. SPRY ranks #51 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
934,423 | $104,048,001 | |
| 2 | VERA |
Vera Therapeutics, Inc.
|
2,173,286 | $87,431,295 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
2,885,622 | $67,408,129 | |
| 4 | CLDX |
Celldex Therapeutics, Inc.
|
1,788,016 | $56,715,867 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
924,193 | $53,704,855 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
632,100 | $47,464,389 | |
| 7 | GERN |
Geron Corp
|
18,834,883 | $28,063,975 | |
| 8 | TVTX |
Travere Therapeutics, Inc.
|
542,610 | $16,120,943 |
All Filings in SPRY
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,093,967 | 136,235 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,931,058 | 251,593 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $9,813,935 | 976,511 | Shares | Sole | 2025-11-14 | |
| 2023-06-30 | $326,879 | 48,788 | Shares | Sole | 2023-11-08 | |
| No filing history on record for this holder in this stock. | ||||||